

Furosemide Injection Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 10/12/2017 |
| 3.2 | 04/12/2018 | 632214-00006 | Date of first issue: 05/03/2016 |

SECTION 1. IDENTIFICATION

Product name : Furosemide Injection Formulation

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc

Address : 2000 Galloping Hill Road
Kenilworth - New Jersey - U.S.A. 07033

Telephone : 908-740-4000

Telefax : 908-735-1496

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with 29 CFR 1910.1200

Specific target organ : Category 1 (Kidney, Liver)
systemic toxicity - repeated exposure

GHS label elements

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H372 Causes damage to organs (Kidney, Liver) through prolonged or repeated exposure.

Precautionary Statements : **Prevention:**
P260 Do not breathe mist or vapors.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.

Response:
P314 Get medical advice/ attention if you feel unwell.

Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.

Furosemide Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 10/12/2017
3.2 04/12/2018 632214-00006 Date of first issue: 05/03/2016

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Hazardous ingredients

| Chemical name | CAS-No. | Concentration (% w/w) |
|---------------|---------|-----------------------|
| Furosemide | 54-31-9 | >= 5 - < 10 |

SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately., When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
Get medical attention if symptoms occur.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Get medical attention if symptoms occur.
- In case of eye contact : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Causes damage to organs through prolonged or repeated exposure.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists.
- Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire fighting : Exposure to combustion products may be a hazard to health.

Furosemide Injection Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 10/12/2017 |
| 3.2 | 04/12/2018 | 632214-00006 | Date of first issue: 05/03/2016 |

- Hazardous combustion products : Nitrogen oxides (NO_x)
Carbon oxides
Sulfur oxides
Chlorine compounds
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.
- Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.
-

SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice and personal protective equipment recommendations.
- Environmental precautions : Discharge into the environment must be avoided.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g., by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
-

SECTION 7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Avoid inhalation of vapor or mist.
Do not swallow.
-

Furosemide Injection Formulation

Version 3.2 Revision Date: 04/12/2018 SDS Number: 632214-00006 Date of last issue: 10/12/2017
 Date of first issue: 05/03/2016

Avoid contact with eyes.
 Avoid prolonged or repeated contact with skin.
 Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
 Take care to prevent spills, waste and minimize release to the environment.

- Conditions for safe storage : Keep in properly labeled containers.
 Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
 Strong oxidizing agents
 Organic peroxides
 Explosives
 Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

| Components | CAS-No. | Value type (Form of exposure) | Control parameters / Permissible concentration | Basis |
|------------|---------|-------------------------------|--|----------|
| Furosemide | 54-31-9 | TWA | 200 µg/m ³ | Internal |
| | | TWA | OEB 2 (>=100 - 1000 µg/m ³) | Internal |

- Engineering measures** : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
 Laboratory operations do not require special containment.

Personal protective equipment

- Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

- Hand protection
 Material : Chemical-resistant gloves

Furosemide Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 10/12/2017
3.2 04/12/2018 632214-00006 Date of first issue: 05/03/2016

Relative density : No data available

Density : No data available

Solubility(ies)
 Water solubility : No data available

Partition coefficient: n-
 octanol/water : No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity
 Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Particle size : Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-
 tions : Can react with strong oxidizing agents.

Conditions to avoid : None known.

Incompatible materials : Oxidizing agents

Hazardous decomposition
 products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION**Information on likely routes of exposure**

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg

Furosemide Injection Formulation

Version 3.2 Revision Date: 04/12/2018 SDS Number: 632214-00006 Date of last issue: 10/12/2017
Date of first issue: 05/03/2016

Method: Calculation method

Components:**Furosemide:**

Acute oral toxicity : LD50 (Rat): 2,600 mg/kg
LD50 (Dog): 2,000 mg/kg
LD50 (Rabbit): 800 mg/kg

Acute toxicity (other routes of administration) : LD0 (Humans): 6 - 29 mg/kg
Application Route: Intravenous
LD50 (Rat): 800 mg/kg
Application Route: Intravenous

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Germ cell mutagenicity

Not classified based on available information.

Components:**Furosemide:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Test system: mouse lymphoma cells
Result: positive

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Test system: mammalian liver cells
Result: negative

Test Type: Chromosome aberration test in vitro
Test system: Chinese hamster ovary cells
Result: positive

Test Type: In vitro sister chromatid exchange assay in mammalian cells

Furosemide Injection Formulation

Version 3.2 Revision Date: 04/12/2018 SDS Number: 632214-00006 Date of last issue: 10/12/2017
Date of first issue: 05/03/2016

Test system: Chinese hamster cells

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)

Species: Chinese hamster
Application Route: Ingestion
Result: negative

Carcinogenicity

Not classified based on available information.

Components:**Furosemide:**

Species : Rat
Application Route : Ingestion
Exposure time : 104 weeks
LOAEL : 16 mg/kg body weight
Result : equivocal

Species : Mouse
Application Route : Ingestion
Exposure time : 2 Years
LOAEL : 91 mg/kg body weight
Result : positive

IARC No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Not classified based on available information.

Components:**Furosemide:**

Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
General Toxicity Parent: NOAEL: 90 mg/kg body weight
Result: No effects on reproduction parameters.

Furosemide Injection Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 10/12/2017 |
| 3.2 | 04/12/2018 | 632214-00006 | Date of first issue: 05/03/2016 |

Test Type: One-generation reproduction toxicity study
 Species: Mouse
 Application Route: Ingestion
 General Toxicity Parent: NOAEL: 200 mg/kg body weight
 Result: No effects on reproduction parameters.

Effects on fetal development : Test Type: Fertility/early embryonic development
 Species: Rat
 Application Route: Ingestion
 General Toxicity Maternal: LOAEL: 50 mg/kg body weight
 Developmental Toxicity: NOAEL: 300 mg/kg body weight
 Result: No embryotoxic effects., No teratogenic effects.

Test Type: Fertility/early embryonic development
 Species: Mouse
 Application Route: Ingestion
 General Toxicity Maternal: LOAEL: 25 mg/kg body weight
 Result: Maternal toxicity observed., Fetal effects.

Test Type: Fertility/early embryonic development
 Species: Rabbit
 Application Route: Ingestion
 General Toxicity Maternal: LOAEL: <= 12 mg/kg body weight
 Developmental Toxicity: LOAEL: 12.5 mg/kg body weight
 Result: Maternal toxicity observed., Reduced number of viable fetuses.

Test Type: Fertility/early embryonic development
 Species: Rabbit
 Application Route: Ingestion
 General Toxicity Maternal: LOAEL: 15 mg/kg body weight
 Result: Maternal toxicity observed., No effects on fetal development.

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Causes damage to organs (Kidney, Liver) through prolonged or repeated exposure.

Components:

Furosemide:

Routes of exposure : Ingestion
 Target Organs : Kidney
 Assessment : Shown to produce significant health effects in animals at concentrations of 10 mg/kg bw or less.

Repeated dose toxicity

Components:

Furosemide:

Species : Dog
 NOAEL : 4 mg/kg

Furosemide Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 10/12/2017
3.2 04/12/2018 632214-00006 Date of first issue: 05/03/2016

LOAEL : 8 mg/kg
Application Route : Ingestion
Exposure time : 12 Months
Target Organs : Kidney
Symptoms : Blood disorders
Remarks : Significant toxicity observed in testing

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****Furosemide:**

Inhalation : Remarks: May be harmful if inhaled.
Skin contact : Remarks: May irritate skin.
Eye contact : Remarks: May cause eye irritation.
Ingestion : Symptoms: Kidney disorders, Headache, electrolyte imbalance, dry mouth, hearing loss, Irregular cardiac activity, Gastrointestinal disturbance, hypotension

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Furosemide:**

Toxicity to fish : LC50: 500 mg/l
Exposure time: 96 h

Persistence and degradability

No data available

Bioaccumulative potential**Components:****Furosemide:**

Partition coefficient: n-octanol/water : log Pow: 2.03

Mobility in soil

No data available

Other adverse effects

No data available

Furosemide Injection Formulation

Version 3.2 Revision Date: 04/12/2018 SDS Number: 632214-00006 Date of last issue: 10/12/2017
 Date of first issue: 05/03/2016

California Prop. 65

This product does not contain any chemicals known to the State of California to cause cancer, birth, or any other reproductive defects.


The ingredients of this product are reported in the following inventories:

AICS : not determined
 DSL : not determined
 IECSC : not determined

SECTION 16. OTHER INFORMATION

Further information

NFPA 704:



HMIS® IV:

| | | |
|------------------------|----------|----------|
| HEALTH | * | 3 |
| FLAMMABILITY | 1 | |
| PHYSICAL HAZARD | 0 | |

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Oth-

Furosemide Injection Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 10/12/2017 |
| 3.2 | 04/12/2018 | 632214-00006 | Date of first issue: 05/03/2016 |

erwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 04/12/2018

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8